← FDA DRUG APPROVALS

FDA BLA · BLA103964

PEGASYS

peginterferon alfa-2a

Sponsor: Pharmaand GmbH

APPLICATION
BLA103964
TYPE
BLA
ORIGINAL APPROVAL
2002-10-16
LATEST ACTION
2023-12-11
ROUTE
SUBCUTANEOUS
DOSAGE FORM
SYRINGE, VIAL
MARKETING STATUS
Prescription

Products

PEGASYSPrescription
PEGINTERFERON ALFA-2A 180U/5ML · SYRINGE
PEGASYSPrescription
PEGINTERFERON ALFA-2A 180UG/VIAL · VIAL · SUBCUTANEOUS

Approval history

2023-12-11Efficacy · Supplement 5276 · standardLabelAP
2021-03-24Labeling · Supplement 5275 · standardLetterAP
2020-10-15Labeling · Supplement 5273 · standardLetterAP
2017-10-13Efficacy · Supplement 5270 · standardLabelAP
2015-03-18Labeling · Supplement 5264 · standardLabelAP
2014-09-05Labeling · Supplement 5261 · standardLabelAP
2013-07-02Labeling · Supplement 5245 · standardLabelAP
2013-05-16Labeling · Supplement 5241 · standardLabelAP
2011-09-29Efficacy · Supplement 5204 · standardLabelAP
2011-08-22Efficacy · Supplement 5213 · priorityLabelAP
2011-08-09Efficacy · Supplement 5186 · standardLabelAP
2011-05-27Efficacy · Supplement 5184 · standardLabelAP
2011-05-09Labeling · Supplement 5216 · standardAP
2011-02-23Labeling · Supplement 5183 · standardLabelAP
2010-05-24Labeling · Supplement 5176 · standardLetterAP
2010-03-03Labeling · Supplement 5177 · standardLetterAP
2009-08-07Labeling · Supplement 5171 · standardAP
2009-04-20Labeling · Supplement 5163 · standardLabelAP
2009-04-20Labeling · Supplement 5147 · standardLabelAP
2008-10-31Labeling · Supplement 5133 · standardLetterAP
2008-09-18Labeling · Supplement 5154 · standardLabelAP
2008-06-13Labeling · Supplement 5144 · standardAP
2008-06-13Labeling · Supplement 5139 · standardAP
2007-06-19Labeling · Supplement 5120 · standardLetterAP
2005-11-18Labeling · Supplement 5076 · standardAP
2005-05-13Efficacy · Supplement 5037 · standardLabelAP
2005-05-13Labeling · Supplement 5065 · standardLetterAP
2005-05-13Labeling · Supplement 5057 · standardLetterAP
2005-02-25Efficacy · Supplement 5039 · priorityLabelAP
2004-12-21Labeling · Supplement 5036 · standardLabelAP
2003-10-31Labeling · Supplement 5016 · standardAP
2002-12-03Efficacy · Supplement 5000 · priorityLetterAP
2002-10-16Type 1 - New Molecular Entity · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →